肝细胞-话题@MedSci

#肝细胞#

513篇内容 | 2590人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1863597, encodeId=b541186359e0f, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, objectType=article, longId=216786, objectId=af4a216e8623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4a216e8623, replyNumber=0, likeNumber=75, createdTime=2022-04-01, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4a216e8623, moduleTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4a216e8623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863680, encodeId=42f618636808e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关, objectType=article, longId=736018, objectId=8b06e36018f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b06e36018f7, replyNumber=0, likeNumber=91, createdTime=2023-02-02, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b06e36018f7, moduleTitle=European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b06e36018f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863668, encodeId=6960186366821, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=CGH:恶病质在肝细胞癌患者中普遍存在并与更差的预后相关, objectType=article, longId=726393, objectId=1de8e26393ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1de8e26393ac, replyNumber=0, likeNumber=0, createdTime=2023-03-22, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1de8e26393ac, moduleTitle=CGH:恶病质在肝细胞癌患者中普遍存在并与更差的预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1de8e26393ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863655, encodeId=8e57186365592, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, objectType=article, longId=299277, objectId=87e42992e798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87e42992e798, replyNumber=0, likeNumber=73, createdTime=2022-12-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87e42992e798, moduleTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87e42992e798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863603, encodeId=191a18636033f, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果, objectType=article, longId=217674, objectId=aa6321e674ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6321e674ae, replyNumber=0, likeNumber=79, createdTime=2022-08-09, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6321e674ae, moduleTitle=CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6321e674ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863596, encodeId=68981863596d0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：肝细胞癌患者免疫检查点抑制剂（ICI）治疗期间使用抗生素缩短生存时间, objectType=article, longId=216031, objectId=4df92160316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4df92160316b, replyNumber=0, likeNumber=69, createdTime=2022-05-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4df92160316b, moduleTitle=Liver Cancer：肝细胞癌患者免疫检查点抑制剂（ICI）治疗期间使用抗生素缩短生存时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4df92160316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863612, encodeId=578e1863612e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=J Hepatol：一种预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险的人工智能模型：PLAN-B, objectType=article, longId=218649, objectId=b92d2186494a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b92d2186494a, replyNumber=0, likeNumber=79, createdTime=2021-12-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b92d2186494a, moduleTitle=J Hepatol：一种预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险的人工智能模型：PLAN-B, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b92d2186494a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863623, encodeId=058f1863623a5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=73, createdTime=2021-12-27, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863633, encodeId=4020186363333, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, objectType=article, longId=264987, objectId=306f26498e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306f26498e26, replyNumber=0, likeNumber=0, createdTime=2022-09-18, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306f26498e26, moduleTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306f26498e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863591, encodeId=743618635914c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：重新定义中期肝细胞癌的肿瘤负荷：7-11标准, objectType=article, longId=214678, objectId=deda2146e818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=deda2146e818, replyNumber=0, likeNumber=66, createdTime=2022-05-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=deda2146e818, moduleTitle=Liver Cancer：重新定义中期肝细胞癌的肿瘤负荷：7-11标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=deda2146e818)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863592, encodeId=8d9b1863592d5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Br J Cancer：SLC38A4调控Wnt/β-catenin/MYC/HMGCS2信号通路抑制肝细胞癌的发生发展, objectType=article, longId=214725, objectId=854e214e25ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=854e214e25ee, replyNumber=0, likeNumber=75, createdTime=2021-12-08, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=854e214e25ee, moduleTitle=Br J Cancer：SLC38A4调控Wnt/β-catenin/MYC/HMGCS2信号通路抑制肝细胞癌的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=854e214e25ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863615, encodeId=706a1863615a2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, objectType=article, longId=219192, objectId=ab6d21919256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6d21919256, replyNumber=0, likeNumber=70, createdTime=2022-06-08, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6d21919256, moduleTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6d21919256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863598, encodeId=e3cc1863598b9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Clin Gastroenterology H: HBeAg 对慢性乙型肝炎患者口服抗病毒药物治疗期间肝细胞癌风险的影响, objectType=article, longId=217119, objectId=e86e21e119cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e86e21e119cf, replyNumber=0, likeNumber=87, createdTime=2021-11-05, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e86e21e119cf, moduleTitle=Clin Gastroenterology H: HBeAg 对慢性乙型肝炎患者口服抗病毒药物治疗期间肝细胞癌风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e86e21e119cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863667, encodeId=213e186366e60, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌, objectType=article, longId=726090, objectId=0c95e260900a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c95e260900a, replyNumber=0, likeNumber=98, createdTime=2022-10-27, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c95e260900a, moduleTitle=Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c95e260900a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863632, encodeId=391e186363201, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：新开发的改良ALBI分级显示更好的肝细胞癌预后和预测价值, objectType=article, longId=264974, objectId=fc8b2649e44f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc8b2649e44f, replyNumber=0, likeNumber=73, createdTime=2022-02-10, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc8b2649e44f, moduleTitle=Liver Cancer：新开发的改良ALBI分级显示更好的肝细胞癌预后和预测价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc8b2649e44f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863571, encodeId=a9b218635e1d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=JNCCN：诊断和治疗的延迟对肝细胞癌患者的影响, objectType=article, longId=212402, objectId=377d2124026c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=377d2124026c, replyNumber=0, likeNumber=65, createdTime=2021-07-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=377d2124026c, moduleTitle=JNCCN：诊断和治疗的延迟对肝细胞癌患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=377d2124026c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863631, encodeId=e6fd1863631e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：影像学应答是伴有肉眼血管侵犯(MVI)的晚期肝细胞癌患者应用TACE+RT治疗时的显著预后指标, objectType=article, longId=221712, objectId=37eb221e1225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37eb221e1225, replyNumber=0, likeNumber=89, createdTime=2022-08-18, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37eb221e1225, moduleTitle=Liver Cancer：影像学应答是伴有肉眼血管侵犯(MVI)的晚期肝细胞癌患者应用TACE+RT治疗时的显著预后指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37eb221e1225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863569, encodeId=e503186356984, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=ASCO 2021: 摘要概览与展望 17 | 肝细胞癌重磅研究进展（第二期）, objectType=article, longId=212157, objectId=195421215ead, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=195421215ead, replyNumber=0, likeNumber=58, createdTime=2021-07-07, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=195421215ead, moduleTitle=ASCO 2021: 摘要概览与展望 17 | 肝细胞癌重磅研究进展（第二期）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=195421215ead)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863665, encodeId=801d1863665a7, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=European Radiology：热消融在肝细胞癌治疗中的价值, objectType=article, longId=725952, objectId=a675e25952f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a675e25952f0, replyNumber=0, likeNumber=122, createdTime=2023-04-16, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a675e25952f0, moduleTitle=European Radiology：热消融在肝细胞癌治疗中的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a675e25952f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863660, encodeId=e8cc186366074, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Lancet Oncol：NAFLD相关肝细胞癌的临床特征及预后, objectType=article, longId=300612, objectId=96c030061203, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96c030061203, replyNumber=0, likeNumber=91, createdTime=2022-08-15, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96c030061203, moduleTitle=Lancet Oncol：NAFLD相关肝细胞癌的临床特征及预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96c030061203)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肝细胞

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究

2022-04-01

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关

2023-02-02

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

CGH:恶病质在肝细胞癌患者中普遍存在并与更差的预后相关

2023-03-22

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS

2022-12-24

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果

2022-08-09

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：肝细胞癌患者免疫检查点抑制剂（ICI）治疗期间使用抗生素缩短生存时间

2022-05-19

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

J Hepatol：一种预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险的人工智能模型：PLAN-B

2021-12-19

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2021-12-27

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效

2022-09-18

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：重新定义中期肝细胞癌的肿瘤负荷：7-11标准

2022-05-19

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Br J Cancer：SLC38A4调控Wnt/β-catenin/MYC/HMGCS2信号通路抑制肝细胞癌的发生发展

2021-12-08

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效

2022-06-08

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Clin Gastroenterology H: HBeAg 对慢性乙型肝炎患者口服抗病毒药物治疗期间肝细胞癌风险的影响

2021-11-05

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌

2022-10-27

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：新开发的改良ALBI分级显示更好的肝细胞癌预后和预测价值

2022-02-10

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

JNCCN：诊断和治疗的延迟对肝细胞癌患者的影响

2021-07-19

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：影像学应答是伴有肉眼血管侵犯(MVI)的晚期肝细胞癌患者应用TACE+RT治疗时的显著预后指标

2022-08-18

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

ASCO 2021: 摘要概览与展望 17 | 肝细胞癌重磅研究进展（第二期）

2021-07-07

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

European Radiology：热消融在肝细胞癌治疗中的价值

2023-04-16

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Lancet Oncol：NAFLD相关肝细胞癌的临床特征及预后

2022-08-15

科室
- - 订阅+
  - 更多科室
工具
服务